Hypertension Management with Amlodipine and Hydralazine

Mechanism of Action and Classification

Amlodipine is a dihydropyridine calcium channel blocker (CCB) that works by blocking calcium influx into vascular smooth muscle cells, causing vasodilation 1

Amlodipine demonstrates dose-dependent antihypertensive effects starting at 2.5mg with optimal effects at 5-10mg daily 1

Amlodipine has robust evidence from large randomized controlled trials (like ALLHAT) showing it is equally effective as thiazide diuretics in preventing coronary heart disease mortality and morbidity 2, 1
Amlodipine-based therapy reduces the incidence of fatal and non-fatal strokes by 25% compared to atenolol-based therapy in diabetic patients 1

Amlodipine is recommended as a first-line agent for hypertension by major guidelines including the American Heart Association and American College of Cardiology (AHA/ACC) and the World Health Organization (WHO) 3
Hydralazine is primarily recommended as a later-line option for resistant hypertension when first-line therapies fail, as suggested by the European Society of Cardiology (ESC) 4
The European Society of Cardiology (ESC) positions hydralazine as a consideration only after spironolactone, eplerenone, beta-blockers, and alpha-blockers have been tried in resistant hypertension 4

Amlodipine is particularly effective in black patients for preventing heart failure and stroke compared to ACE inhibitors, according to the American College of Cardiology 3
Amlodipine can be used in heart failure patients with persistent hypertension as a step 3 agent, as recommended by the American College of Cardiology 5, 1
Hydralazine has a specific role in acute hypertensive emergencies (administered intravenously) and in pregnancy-related hypertension, as noted by the European Heart Journal 4

Both medications are available as generic formulations, but amlodipine is more widely used globally, as reported by the American College of Cardiology 1